Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
13
Not yet recruiting, industry sponsors, Kidney and urology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed218
13 trials
Showing 1 to 13, recently updated first.
- A Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney FunctionNot yet recruiting
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyIndustry
NCT07924930 · 32 participants (planned) · Start Nov 2026 · Primary completion Aug 2027
Drug: Tersolisib · For: Renal Insufficiency; Healthy Participant
Sites: Altamonte Springs, Florida; Miami Lakes, Florida
- Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney DiseaseNot yet recruiting
Cajal Therapeutics Inc.Industry
NCT07901933 · 24 participants (planned) · Start Nov 2026 · Primary completion Oct 2027
Drug: Placebo; CTX001 and 1 more · For: Chronic Kidney Disease; Anemia
Sites: Gosford, Australia; St Leonards, Australia; Southport, Australia · 4 sites in all
- A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese ParticipantsNot yet recruiting
Triastek, lnc.Industry
NCT07897240 · 18 participants (planned) · Start Oct 2026 · Primary completion Dec 2026
Drug: Budesonide delayed release tablet · For: IgA Nephropathy
Sites: Suzhou, China
- IBI3034 Study in Healthy Adults and Patients With Primary IgA NephropathyPivotal-lookingNot yet recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07886476 · 100 participants (planned) · Start Oct 15, 2026 · Primary completion Jan 31, 2027
Drug: IBI3034; Placebo and 1 more · For: IgA Nephropathy (IgAN)
Sites: Beijing, China
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney DiseasesNot yet recruiting
Grit BiotechnologyIndustry
NCT07389499 · 30 participants (planned) · Start Aug 2027 · Primary completion Jun 30, 2028
Drug: CD19-targeted iNKT Cell Injection · For: IgA Nephropathy (IgAN); Membranous Nephropathy; ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN) and 2 more
Sites: Shanghai, China
- A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney FunctionNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07808788 · 54 participants (planned) · Start Sep 4, 2026 · Primary completion Jul 6, 2027
Drug: NNC0537-1482 · For: Chronic Kidney Disease
Sites: Berlin, Germany
- A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male VolunteersNot yet recruiting
Addpharma Inc.Industry
NCT07722871 · 44 participants (planned) · Start Jul 2026 · Primary completion Oct 2026
Drug: AD-116A; AD-1161 · For: Benign Prostatic Hyperplasia
Sites: Seoul, South Korea
- A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male VolunteersNot yet recruiting
Addpharma Inc.Industry
NCT07715305 · 44 participants (planned) · Start Jul 2026 · Primary completion Aug 2026
Drug: AD-116A; AD-1161 · For: Benign Prostatic Hyperplasia
Sites: Seoul, South Korea
- Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed ConditionsNot yet recruiting
AJU Pharm Co., Ltd.Industry
NCT07643233 · 36 participants (planned) · Start Jul 2026 · Primary completion Jul 2026
Drug: Test Drug; Reference Drug · For: Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Sites: Seoul, South Korea
- A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male SubjectsNot yet recruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07557407 · 6 participants (planned) · Start May 2026 · Primary completion Jun 2026
Drug: [14C]HRS-1780 · For: Chronic Kidney Diseases
Sites: Jinan, China
- Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene TherapyNot yet recruiting
Cyllene TherapeuticsIndustry
NCT07227285 · 16 participants (planned) · Start Apr 2026 · Primary completion Apr 2031
Drug: EG110A · For: Urinary Bladder, Overactive; Spinal Cord Injury
Sites: Downey, California; Ann Arbor, Michigan; Philadelphia, Pennsylvania · 4 sites in all
- A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy VolunteersNot yet recruiting
Klotho Sciences Australia Pty Ltd.Industry
NCT07143331 · 84 participants (planned) · Start Aug 30, 2025 · Primary completion Apr 1, 2026
Drug: Part 1 KS101; Part 1 Placebo and 3 more · For: Healthy Participants; Alzheimer Disease; Chronic Kidney Disease
Sites: Sydney, Australia
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruiting
Sinocelltech Ltd.Industry
NCT06774664 · 99 participants (planned) · Start Jan 2025 · Primary completion Sep 2027
Drug: SCTC21C · For: IgA Nephropathy
Sites: Baotou, China; Beijing, China; Chengdu, China · 20 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.